Abstract Details

Title Cardiac Safety and Rates of Sudden Unexplained Death in Patients with Partial-Onset Epilepsy Treated with Ezogabine (Retigabine)

Topic Epilepsy

Presentation(s) (-)

Poster/Presentation
Number 208

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
	No disclosure on file
Janet M. Hammond, MD, PhD (Valeant Pharmaceuticals)	No disclosure on file
Kevan E. VanLandingham, MD, PhD, FAAN (US Food and Drug Administration)	Dr. VanLandingham has received personal compensation for serving as an employee of Greenwich Biosciences. Dr. VanLandingham has received stock or an ownership interest from Greenwich Biosciences.
Sarah E. DeRossett, MD, PhD	No disclosure on file
	No disclosure on file
Thibault Moreau	Thibault Moreau has nothing to disclose.

��ɫ��